BioSpace News Archive

The system, which is manufactured by Fremont, California-based THINK Surgical, Inc., features a fully active robot for orthopedic surgery.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 2,383,090 shares of common stock of OncoCyte Corporation at a price to buyers of $2.156 per share, representing the average closing price of OncoCyte common stock over the five trading days prior to the execution of the agreement.

VASCEPA becomes the first and only Health Canada approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the studied high-risk patients approved for treatment

Exact Sciences Corp. announced that company management will participate in the following investor conference and invited investors to participate by webcast.

The company will provide an overview of the business and discuss recent corporate achievements that position it to further extend its leadership in the market.

An opinion from the EMA’s Committee for Medicinal Products for Human Use on the MAA for Roclanda® is expected in late 2020.

The presentation is scheduled for Thursday, January 16, 2020 at 10:30 a.m. PST

Dr. van Es-Johansson currently serves as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance.

Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will provide a corporate update at the conference

David A. Ricks, Lilly’s chairman and chief executive officer, will participate in a fireside chat at 5:30 p.m. Eastern time.